B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry
Detect minimal residual disease in patients of all ages previously diagnosed with B-ALL.
New York DOH Approval Status
Bone marrow. Whole blood: Green (sodium heparin) or lavender (EDTA).
Transport 2 mL heparinized bone marrow (Min: 1.0 mL*) OR 3 mL whole blood (Min: 1mL*)
Room temperature. Also acceptable: Refrigerated. Specimen should be received within 24 hours of collection for optimal cell viability.
Clotted or hemolyzed specimens.
Provide specimen source, CBC, Wright stained smear (if available), clinical history, differential diagnosis.
Follow up: If previous leukemia/lymphoma phenotyping was performed at another lab, the outside flow cytometry report and histograms (if possible) should accompany the specimen.
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Refer to report.
Analyte Specific Reagent (ASR)
This assay is a minimal residual disease assessment of B-ALL by flow cytometry.
Available markers*: CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16, CD66b, CD24, CD22
*Not all markers will be reported in all cases.
If COG panel is not specified, a 10-marker panel will be run:
CD10, CD19, CD20, CD22, CD24, CD34, CD38, CD45, CD58, CD66b
If COG panel is specified, indicate time point and specimen type:
DAY 8 Peripheral blood sample will have CD10, CD19, CD20, CD34, CD45, and Syto 16 run and reported. (6 markers total).
Day 29 Bone marrow sample will have CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16 run and reported. (13 markers total).
The report will include a pathologist interpretation and a marker interpretation range corresponding to CPT codes of 2-8 markers or 9-15 markers interpreted. Charges apply per marker.
88184; 88185 each additional marker; 88187 or 88188.
|Component Test Code*||Component Chart Name||LOINC|
|3000737||Number of Markers||19099-1|
|3000738||B-All MRD Interpretation||45267-2|
- Acute Leukemia Follow up Phenotyping by Flow Cytometry
- Follow-Up Phenotyping
- Hematopoietic neoplasms monitoring
- Leukemia/Lymphoma Evaluation Panel
- Leukemia/Lymphoma Phenotyping, Comprehensive - Bone Marrow
- Leukemia/Lymphoma Phenotyping, Comprehensive - Miscellaneous
- Leukemia/Lymphoma Phenotyping, Comprehensive - Whole Blood